Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
80 hedge funds and large institutions have $132M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 19 closing their positions.
136% more call options, than puts
Call options by funds: $5.78M | Put options by funds: $2.45M
19% more capital invested
Capital invested by funds: $111M → $132M (+$21.4M)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
4% less funds holding
Funds holding: 83 → 80 (-3)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.47M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.8M |
| 3 |
Goldman Sachs
New York
|
+$1.11M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.11M |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$868K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.64M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.34M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.79M |
| 4 |
First Eagle Investment Management
New York
|
-$1.44M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.27M |
VIRX Hedge Fund Activity: Q2 2015 in Review
80 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2015, worth a combined $132M — up 19% from $111M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VIRX and 16 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 23 added.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $5.47M. The largest seller was BVF Inc, exiting entirely with an estimated $4.64M sold.
- 80 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2015, down from 83 in Q1 2015.
- Funds reported $132M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2015, up 19% quarter-over-quarter.
- 16 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2015 and 19 closed out, a net change of -3 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2015 was Farallon Capital Management, an estimated $5.47M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2015 was BVF Inc, an estimated $4.64M sold.
Based on aggregated 13F filings for Q2 2015.